Immune recovery following switch from EFV-based regimens to bictegravir/emtricitabine/tenofovir alafenamide in virologically suppressed immunological non-responders: a 144-week real-world cohort study in China. - Yang H; Yu Q; Li M; Liu M (Frontiers in immunology, 2026)